![institutions-DFCI-Logo-500px-rgb[2]20221027132117.jpg](/images/institutions/logos/DFCI-Logo-500px-rgb[2]20221027132117.jpg){kind=logo}
Prom season and summer approach, and with them teenage girls seeking suntans. New research published in the May issue of Pediatrics finds that the number of children diagnosed with melanoma has increased an average 2% a year since the 1970s.
Dana-Farber investigators led a phase 1 trial in which a new oral targeted drug, idelalisib, (GS-1101), showed the potential to stave off the need for additional treatments for relapsed or treatment-resistant CLL.
Emil “Tom” Frei, III, MD, who is credited for helping prove the efficacy of combination chemotherapy, died. Dr. Frei, along with Emi Freireich, MD, and James Holland, MD, demonstrated a half century ago, that multiple chemotherapy agents could produce lasting remissions in children with acute lymphocytic leukemia.
A type of low-grade but sometimes lethal brain tumor in children has been found in many cases to contain an unusual mutation that may help to classify, diagnose and guide the treatment of the tumors, report scientists at Dana-Farber Cancer Institute.
The stem cell transplant regimen that was commonly used in the United States to treat advanced neuroblastoma in children appears to be more toxic than the equally effective regimen employed in Europe and Egypt, according to a new study that helped inform the recent decision of the Children’s Oncology Group to switch to the European regimen, says a researcher at Dana-Farber/Children’s Hospital Cancer Center in Boston.
Almost two-thirds of children who receive stem cell transplants are readmitted to the hospital within six months, according to researchers at Dana-Farber/Children’s Hospital Cancer Center in Boston.
When the eye cancer retinoblastoma is diagnosed in racial and ethnic minority children whose families don’t have private health insurance, it often takes a more invasive course than in other children, probably because of delays in diagnosis, according to researchers at Dana-Farber/Children’s Hospital Cancer Center in Boston.
An irregularity within many neuroblastoma cells may indicate whether the tumor is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors
Dana-Farber scientists find when given together, two orally available experimental drugs — sapacitabine and seliciclib — worked together to elicit antitumor effects in patients with incurable BRCA-deficient cancers.
Dana-Farber researchers find blood test can provide fuller picture of cancer mutations in gastrointestinal stromal tumors than biopsy
Dana-Farber researchers find novel antibody-guided drug achieves responses in platinum drug-resistant ovarian cancer.
Dana-Farber scientists have found that pancreatic cancer cells’ growth and spread are fueled by an unusual metabolic pathway that someday might be blocked with targeted drugs to control the deadly cancer.
New research led by scientists at Dana-Farber Cancer Institute, the Broad Institute, and other research centers, may offer clues to why rates of esophageal adenocarcinomas (EAC) have risen so sharply. The findings point to abnormal genes and proteins that may be lynchpins of EAC cell growth and therefore serve as targets for new therapies.
A new report that breast cancer patients treated with low doses of radiation therapy have a heightened risk of heart disease suggests that physicians need to work with patients before, during, and after treatment to minimize that risk, according to an accompanying editorial in the March 14 issue of the New England Journal of Medicine
Dana-Farber Cancer Institute has launched a free, easy-to-use iPhone® app that provides recipes and nutrition information that can be searched by cancer patients in accordance with their needs. The recipes are also helpful to anyone who wants to have a healthy diet.
A study led by Dana-Farber Cancer Institute and Broad Institute researchers shows how gene mutations shift and evolve over time in chronic lymphocytic leukemia (CLL). This evolution, they report, holds the key to understanding why CLL often recurs after treatment and helps explain why patients often don’t derive the same benefit.
Large-scale genomic sequencing has revealed two DNA mutations that appear to drive about 15 percent of meningiomas report Dana-Farber Cancer Institute and Broad Institute scientists. Experimental drugs that inhibit these mutant gene pathways are in clinical trials and have shown promising activity.
A new study that proposes a three-in-one test for gynecologic cancers underscores the promise of molecular screening for early detection of endometrial and ovarian cancers, but also suggests that such tests are not yet ready for clinical use. Andrea Myers, MD, PhD, of Dana-Farber Cancer Institute, a co-author of the commentary on the study, says the test is an important step in that direction.
Dana-Farber Cancer Institute has a free, easy-to-use iPhone® app that provides recipes and nutrition information for cancer patients and anyone who wants to have a healthy diet.
A report from the nation’s leading cancer organizations shows rates of death in the United States from all cancers for men and women continued to decline between 2000 and 2009. The findings come from the latest Annual Report to the Nation on the Status of Cancer.
Researchers at Dana-Farber/Brigham and Women’s Cancer Center report a small percentage of men in a prostate cancer study complained that their penis seemed shorter following treatment, causing them to regret the type of treatment they chose.
The holidays can be a festive and joyful time. But for those who have been affected by cancer, it can be stressful and full of anxiety. Dana-Farber offers tips to help cope this holiday season.
Dana-Farber Cancer Institute scientists have discovered a molecular switch that enables advanced prostate cancers to spread without stimulation by male hormones. This previously unknown protein function could serve as a treatment target for prostate cancers that are no longer controlled by hormone-blocking drugs.
Pediatric patients with B-precursor acute lymphoblastic leukemia who are likely to relapse after chemotherapy treatment can reduce those odds by receiving additional courses of chemotherapy, according to research by Dana-Farber/Children’s Hospital Cancer Center investigators.
Dana-Farber researchers found an experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen of care, but that the new combination could provide an alternative that could be preferable in certain scenarios.
Dana-Farber researchers found levels galectin-1, an immunity-related protein, could be the basis of a test and potentially a targeted treatment for Hodgkin lymphoma.
Scientists at Dana-Farber Cancer Institute have isolated a previously unknown protein in muscles that spurs their growth and increased power following resistance exercise. They suggest that artificially raising the protein’s levels might someday help prevent muscle loss caused by cancer, prolonged inactivity in hospital patients, and aging.
A new study by an international team of investigators led by Dana-Farber Cancer Institute scientists is the first to demonstrate that chemotherapy and a new, targeted therapy work better in combination than chemotherapy alone in treating patients with the most common genetic subtype of lung cancer.
A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial.
Dana-Farber expert offers tips to fight cancer with your fork this season
Dana-Farber experts offer life saving information and ways to reduce risk of lung cancer.
Terminally ill cancer patients who have an early talk with their physician about care at the end-of-life are less likely to receive aggressive therapy – and more likely to enter hospice care – than patients who delay such discussions until the days and weeks before death, a new study by Dana-Farber Cancer Institute researchers suggests.
Colon cancer survivors whose diet is heavy in complex sugars and carbohydrate-rich foods are far more likely to have a recurrence of the disease than are patients who eat a better balance of foods, a new study by Dana-Farber Cancer Institute researchers indicates.
Aspirin therapy can extend the life of colorectal cancer patients whose tumors carry a mutation in a key gene, but has no effect on patients who lack the mutation, Dana-Farber Cancer Institute scientists report in the Oct. 25 issue of the New England Journal of Medicine.
Experts at Dana-Farber Cancer Institute help tackle some of the myths and misconceptions about breast cancer risk. They answer some of the more common questions, explain the studies behind the answers, and provide risk-lowering tips.
Erica Mayer, MD, M.P.H., is a breast cancer expert at Dana-Farber Cancer Institute in Boston. She gives at least five simple ways women can reduce their risk of getting the disease.
Dana-Farber researchers have developed a method for determining how ready acute myeloid leukemia cells are to die, a finding that may enable oncologists to choose more effective treatments for their patients.
Researchers have identified a molecular link between thermogenesis and the development of inflammation in fat cells. Activating molecular switch in white fat cells enabled mice to eat a high-calorie diet without becoming obese or developing the inflammation that causes insulin resistance, report Dana-Farber Cancer Institute scientists.
A molecule that targets the cell's machinery for breaking down unneeded proteins can kill multiple myeloma cancer cells resistant to the frontline drug Velcade, Dana-Farber Cancer Institute researchers report. P5091 triggered apoptosis in drug-resistant myeloma cells in the lab and in animals.
A new study by researchers at Dana-Farber Cancer Institute shows a small molecule compound can generate reversible birth control in male mice.
Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard scientists have identified a new class of genes, dubbed CYCLOPS, that may serve as an Achilles' heel for many forms of cancer.
U.S. News & World Report’s Best Hospitals guide has ranked Dana-Farber/Brigham and Women’s Cancer Center the top cancer center in New England and fifth overall in the country. The rankings are now available online at www.usnews.com/besthospitals.
Scientists at Dana-Farber Cancer Institute have isolated a new type of energy-burning fat cell in adult humans which they say may have therapeutic potential for treating obesity.
Dana-Farber reports a novel compound has become the first targeted therapy to benefit patients with the most common genetic subtype of lung cancer.
Researchers at Dana-Farber/Children’s Hospital Cancer Center have devised a strategy to directly activate a natural “death” protein, triggering the self-destruction of cells--which could lead to new possibilities for designing cancer drugs.
Scientists at the Dana-Farber/Children’s Hospital Cancer Center have developed an anti-cancer peptide that overcomes the stubborn resistance to chemotherapy and radiation often encountered in relapsed and refractory blood cancers.
Adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) – an approach approved by the FDA in 2006 – did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare, a new study by Dana-Farber Cancer Institute researchers has found.
Scientists at Dana-Farber Cancer Institute have discovered why diabetic-like symptoms develop in some patients given rapamycin, an immune-suppressant drug that also has shown anti-cancer activity and may even slow ageing.
Scientists have published the first results from the Cancer Cell Line Encyclopedia, a freely available resource that marries deeply detailed cancer genome data with predictors of drug response, information that could lead to refinements in cancer clinical trials and future treatments.
A report from the nation’s leading cancer organizations shows rates of death in the United States from all cancers for men and women continued to decline between 2004 and 2008. The findings come from the latest Annual Report to the Nation on the Status of Cancer.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right